

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Inflammatory Bowel Disease Agents, Rectal PDL Edit <i>(formerly Ulcerative Colitis Agents, Rectal PDL Edit)</i>
<b>First Implementation Date:</b>	June 18, 2009
<b>Proposed Date:</b>	April 18, 2023
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Inflammatory Bowel Disease (IBD) describes disorders such as ulcerative colitis (UC) and Crohn's disease (CD) which involve chronic inflammation in the digestive tract. An estimated 1.3% of US adults reported being diagnosed with IBD in 2015. UC is characterized by recurring inflammation and ulcers in the lining of the colon and rectum. CD is also characterized by inflammation but may involve any portion of the digestive tract, from the oral cavity to the perianal area. Inflammation in CD can affect the entire thickness of the bowel wall and may skip or leave normal areas in between patches of inflammation. Both UC and CD are typically characterized by diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. The goals of IBD therapy are to reduce inflammation, leading to symptom relief and reduced risk of further complications from disease.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>Mesalamine Kit/Supp</li> <li><b>Mesalamine (gen sfRowasa®)</b></li> </ul>	<ul style="list-style-type: none"> <li>Canasa®</li> <li>Rowasa® Enema/Kit</li> <li>sfRowasa® Enema</li> <li>Uceris® Foam</li> </ul>

**Type of Criteria:** ☐ Increased risk of ADE  
☐ Appropriate Indications

☒ Preferred Drug List  
☐ Clinical Edit

**Data Sources:** ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Inflammatory Bowel Disease Agents, Rectal
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
  - Documented trial period of preferred agents **OR**
  - Documented ADE/ADR to preferred agents

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:  
MedWatch Form:


Progress Notes:  
Other:


## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

- Evidence-Based Medicine and Fiscal Analysis: "Ulcerative Colitis Agents, Rectal – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2022.
- Evidence-Based Medicine Analysis: "Ulcerative Colitis Agents (Rectal)", UMKC-DIC; Last updated November 2022.
- Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65:1166–1169. DOI: <http://dx.doi.org/10.15585/mmwr.mm6542a3>external icon.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.